title: The effects of hydroxycinnamic acid derivatives on adiponectin secretion.
abstract: Adiponectin is positively correlated with insulin sensitivity. Hydroxycinnamic acid derivatives (HADs), observed ubiquitously in plants, have some physiological functions. In this study, we investigated the effect of HADs on serum adiponectin concentrations in mice and on adiponectin secretion of 3T3-L1 adipocytes. In mice, serum adiponectin concentrations were increased by gamma-oryzanol administration. CAPE, curcumin, and trans-ferulic acid markedly enhanced the adiponectin secretion of 3T3-L1 adipocytes, but not gamma-oryzanol. To clarify the effects of gamma-oryzanol in mice or the effects of HADs on the underlying mechanisms of adiponectin secretion, we further investigated the effect of HADs on adiponectin secretion in the NF-kappaB activation state. Although the adiponectin secretion was reduced in the presence of lipopolysaccharide plus TNF-alpha and IFN-gamma, only gamma-oryzanol supported the activity of adiponectin secretion under NF-kappaB activated condition. The results indicate that these HADs might regulate adiponectin secretion by the inhibition of NF-kappaB activation. HADs might be effective for ameliorating type 2 diabetes.
authors.affiliation: Department of Food Science and Technology, Tokyo University of Marine Science and Technology, 5-7 Konan 4, Minato, Tokyo 108-8477, Japan.
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Ohara
authors.forename: Asako
authors.initials: A
authors.lastname: Uchida
authors.forename: Reiko
authors.initials: R
authors.lastname: Nagasaka
authors.forename: Hideki
authors.initials: H
authors.lastname: Ushio
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Ohshima
mesh_terms: D041721:3T3-L1 Cells; D017667:Adipocytes / Q000187:drug effects*; D052242:Adiponectin / Q000097:blood / Q000378:metabolism*; D000818:Animals; D002109:Caffeic Acids / Q000494:pharmacology; D003373:Coumaric Acids / Q000494:pharmacology* / Q000627:therapeutic use; D003474:Curcumin / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007333:Insulin Resistance; D007371:Interferon-gamma / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives / Q000494:pharmacology; D010666:Phenylpropionates / Q000494:pharmacology*; D008517:Phytotherapy; D000077205:Pioglitazone; D010936:Plant Extracts / Q000494:pharmacology*; D010938:Plant Oils / Q000494:pharmacology; D000073879:Rice Bran Oil; D045162:Thiazolidinediones / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D052242:Adiponectin; D002109:Caffeic Acids; D003373:Coumaric Acids; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D008070:Lipopolysaccharides; D016328:NF-kappa B; D010666:Phenylpropionates; D010936:Plant Extracts; D010938:Plant Oils; D045162:Thiazolidinediones; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; C004999:ferulic acid; C055494:caffeic acid phenethyl ester; D003474:Curcumin; D000073879:Rice Bran Oil; D010626:Phenylethyl Alcohol; C013172:gamma-oryzanol; D000077205:Pioglitazone